Coincidence detection fdg pet in the management of oncological patients: Attenuation correction versus non-attenuation correction

Nuclear Medicine Communications

Volumn 22, Issue 11, 2001, Pages 1185-1192

  Chan, W L ^a   Freund, J ^a   Pocock, N A ^a   Szeto, E ^a   Chan, F ^a   Sorensen, B J ^a   McBRIDE, B ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

Attenuation correction; Co PET; Fluorodeoxyglucose; Neoplasm

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; IMAGE QUALITY; IMAGING SYSTEM; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; POSITRON EMISSION TOMOGRAPHY; RADIATION ATTENUATION; SCINTILLATION CAMERA;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; GAMMA CAMERAS; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THORACIC NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0034753544     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200111000-00004     Document Type: Review

References (24)

1. Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small cell lung carcinoma. J Nucl Med 1996; 37: 1428-1436.
2. Hoh CK, Glaspy J, Rosen P, et al. Whole-body FDG PET imaging for staging of Hodgkin’s disease and lymphoma. J Nucl Med 1997; 38: 343-348.
3. Newman J, Francis IR, Kaminske MS, Wahl RL. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxyglucose: correlation with CT. Radiology 1994; 190: 111-116.
4. Valk PE, Segall GM, Johnson DL, et al. Cost-effectiveness of whole-body FDG PET imaging in metastatic melanoma. J Nucl Med 1997; 38: 89P.
5. Delbeke D. Oncological applications of FDG PET imaging: brain tumours, colorectal cancer, lymphoma and melanoma. J Nucl Med 1999; 40: 591-603.
6. Schwaiger M, Ziegler S. PET using a coincidence camera versus ring tomography, progress or recession? Nuklearmedizin 1997; 36: 3-5.
7. Delbeke D, Patton JA, Martin WH, Sandler MP. FDG PET and dual-head gamma camera positron coincidence detection imaging of suspected malignancies and brain disorders. J Nucl Med 1999; 40: 110-117.
8. Zimny M, Kaiser HJ, Cremerius U, et al. Fluorine-18-fluorodeoxyglucose positron imaging in oncological patients: gamma camera coincidence detection versus dedicated PET. Nuklearmedizin 1999; 38: 108-114.
9. Sajdak R, Ariola-Pienschke E. Optimized technical considerations for acquiring high-quality FDG studies with a dual-headed gamma camera. J Nucl Med Technol 1998; 26: 245-247.
10. Wagner Jr HN. Clinical PET: its time has come. J Nucl Med 1991; 32: 561-564.
11. Drane WE, Abbott FD, Nicole MW. Technology for FDG SPECT with a relatively inexpensive gamma camera. Work in progress. Radiology 1994; 191: 461-465.
12. Landoni C, Gianolli L, Lucignani G, et al. Comparison of dual-head coincidence PET versus ring PET in tumor patients. J Nucl Med 1999; 40: 1617-1622.
13. Shreve PD, Steventon RS, Deters EC, et al. Oncologic diagnosis with 2-fluorine-18-fluoro-2-deoxy-D-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner. Radiology 1998; 207: 431-437.
14. Boren Jr EL, Delbeke D, Patton JA, et al. Comparison of FDG PET and positron coincidence detection imaging using a dual-head gamma camera with 5/8-inch NaI(Tl) crystals in patients with suspected body malignancies. Eur J Nucl Med 1999; 26: 379-387.
15. Weber WA, Neverve J, Sklarek J, et al. Imaging of lung cancer with fluorine-18 fluorodeoxyglucose: comparison of a dual-head gamma camera in coincidence mode with a full-ring positron emission tomography system. Eur J Nucl Med 1999; 26: 388-395.
16. Shao L, Nellemann P, Muehllehner G, et al. Singles-transmission attenuation correction for dual head coincidence imaging. J Nucl Med 1998; 39(Suppl): 37P.
17. Coleman RE, Laymon CM, Turkington TG. FDG Imaging of lung nodules: a phantom study comparing SPECT, camera-based PET and dedicated PET. Radiology 1999; 210: 823-828.
18. Raylman RR, Kison PV, Wahl RL. Capabilities of two- and three-dimensional FDG-PET for detecting small lesions and lymph nodes in the upper torso: a dynamic phantom study. Eur J Nucl Med 1999; 26: 39-45.
19. Bengel FM, Ziegler SI, Avril N. Whole-body positron emission tomography in clinical oncology: comparison between attenuation corrected and uncorrected images. Eur J Nucl Med 1997; 24: 1091-1098.
20. Zimny M, Kaiser HJ, Cremerius U, et al. Dual-head gamma camera 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography in oncological patients: effects of non-uniform attenuation correction on lesion detection. Eur J Nucl Med 1999; 26: 818-823.
21. Wahl R. To AC or not to AC: that is the question. J Nucl Med 1999; 40: 2025-2028.
22. Knopp MV, Bischoff HG. Evaluation of pulmonary lesions with positron emission tomography. Radiology 1994; 34: 588-591.
23. Lewis P, Griffin S, Marsden P, et al. Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994; 344: 1265-1266.
24. Cook G, Fogelman I, Maisey M. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med 1996; 26: 308-314.